Evidence map›Paper›PMID 39719594›Full record

ArticleHealth and quality of life outcomes2024

Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer.

Ikenna I Nnabugwu, Eric N Obikeze, Chinwe A Nnabugwu, Solomon K Anyimba, Okwudili C Amu, Okezie M Mbadiwe, Kevin S N Echetabu, Ijeoma L Okoronkwo

Abstract read
In one paragraph

Article in Health and quality of life outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Prostate cancer in Nigeria: a scoping review and meta-analysis of current evidence on process indicators and interventions.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ikenna I NnabugwuUrology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria. ikenna.nnabugwu@unn.edu.ng.ORCID http://orcid.org/0000-0001-5469-9265
Eric N ObikezeDepartment of Health Administration and Management, Faculty of Health Sciences and Technology College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria.
Chinwe A NnabugwuDepartment of Health Administration and Management, Faculty of Health Sciences and Technology College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria.
Solomon K AnyimbaUrology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria.
Okwudili C AmuUrology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria.
Okezie M MbadiweUrology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria.
Kevin S N EchetabuUrology Unit, Department of Surgery, Faculty of Medical Sciences, College of Medicine, University of Nigeria, Ituku-Ozalla Enugu, PMB 01129, Nigeria.
Ijeoma L OkoronkwoDepartment of Health Administration and Management, Faculty of Health Sciences and Technology College of Medicine, University of Nigeria Enugu Campus, Enugu, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPerformance status and health-related quality of life (HRQoL) are important parameters in the management of metastatic prostate cancer. The clinician-rated Eastern Cooperative Oncology Group performance status (ECOG-PS) may not relate with the patient-reported HRQoL because the later puts into consideration some aspects of health that are not captured by the former. The aim of this study is to define the relationship between clinician-rated ECOG-PS and the patient-reported HRQoL in men with metastatic hormone-naïve prostate cancer (mPCa).

methodsAn analytical cross-sectional study recruiting patients presenting with mPCa in Enugu, southeast Nigeria. Two clinicians agreed on an ECOG-PS score for each study participant who in turn completed the Functional Assessment in Cancer Therapy - Prostate (FACT-P) and the EuroQol EQ-5D-5 L questionnaires with interviewer-assistance where necessary. Other medical information was retrieved from the records. ANOVA and chi-square tests were used to compare available data across ECOG-PS ratings and ordinal logistic regression was used to determine the FACT-P questionnaire items that related significantly with the ECOG-PS scores.

resultsOf the 224 participants (mean age: 70.62 ± 7.34), about 60.7% had ≥ 12years of formal education and 84.9% had ISUP grade ≥ 3 cancer. In all, 22.8%, 55.8%, 21.0% and 0.4% were ECOG-PS 1, ECOG-PS 2, ECOG-PS 3 and ECOG-PS 4 respectively. The mean FACT-P score, health utility index (HUI) and visual analogue scale (VAS) scores were 80.18 ± 17.56, 0.524 ± 0.324 and 60.43 ± 9.91% respectively. The FACT-P score (p = 0.002), HUI (p < 0.001) and VAS score (p < 0.001) varied significantly across the ECOG-PS ratings. Within the FACT-P, only questionnaire items GP3 (p = 0.024) and GP7 (p < 0.001) of the PWB domain, and items GF5 (p = 0.009) and GF6 (p = 0.003) of the FWB domain related strongly with the ECOG-PS categories.

conclusionThere are indications that HRQoL questionnaire items that have to do with impairment in physical and role functioning relate strongly with ECOG-PS categories.

Indexed as

Prostatic NeoplasmsQuality of LifeAgedCross-Sectional StudiesHealth StatusHumansMaleMiddle AgedNigeriaPatient Reported Outcome MeasuresSurveys and QuestionnairesECOGEQ-5D-5LFACT-PHRQoLMetastatic prostate cancerPerformance status

Identifiers

PMID39719594
PMCPMC11669234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.